Alcobra Ltd. (NASDAQ:ADHD)’s share price traded up 5.2% during trading on Friday . The company traded as high as $4.88 and last traded at $4.86, with a volume of 110,644 shares trading hands. The stock had previously closed at $4.62.

A number of equities analysts recently commented on the company. Cantor Fitzgerald assumed coverage on Alcobra in a report on Tuesday, June 7th. They set a “buy” rating and a $16.00 target price for the company. Canaccord Genuity assumed coverage on Alcobra in a report on Tuesday, June 7th. They set a “buy” rating for the company. Roth Capital restated a “buy” rating and set a $12.00 target price on shares of Alcobra in a report on Tuesday, June 21st. Finally, Zacks Investment Research upgraded Alcobra from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a report on Thursday, April 28th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Alcobra presently has an average rating of “Buy” and a consensus target price of $10.63.

The stock’s market capitalization is $133.95 million. The stock has a 50-day moving average price of $4.80 and a 200-day moving average price of $4.74.

Alcobra (NASDAQ:ADHD) last announced its earnings results on Monday, May 16th. The company reported ($0.18) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.04. Analysts forecast that Alcobra Ltd. will post ($0.98) EPS for the current year.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.